ATE179611T1 - Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv) - Google Patents

Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv)

Info

Publication number
ATE179611T1
ATE179611T1 AT95909937T AT95909937T ATE179611T1 AT E179611 T1 ATE179611 T1 AT E179611T1 AT 95909937 T AT95909937 T AT 95909937T AT 95909937 T AT95909937 T AT 95909937T AT E179611 T1 ATE179611 T1 AT E179611T1
Authority
AT
Austria
Prior art keywords
ns4a
pct
hcv
protease activity
serine protease
Prior art date
Application number
AT95909937T
Other languages
English (en)
Inventor
Francesco Raffaele De
Cristina Failla
Licia Tomei
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE179611T1 publication Critical patent/ATE179611T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95909937T 1994-02-23 1995-02-14 Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv) ATE179611T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940092A IT1272179B (it) 1994-02-23 1994-02-23 Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Publications (1)

Publication Number Publication Date
ATE179611T1 true ATE179611T1 (de) 1999-05-15

Family

ID=11402272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909937T ATE179611T1 (de) 1994-02-23 1995-02-14 Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv)

Country Status (15)

Country Link
US (1) US5739002A (de)
EP (1) EP0746333B1 (de)
JP (1) JP3280384B2 (de)
AT (1) ATE179611T1 (de)
AU (1) AU691259B2 (de)
BR (1) BR9506931A (de)
CA (1) CA2182521C (de)
DE (1) DE69509504T2 (de)
DK (1) DK0746333T3 (de)
ES (1) ES2132644T3 (de)
GR (1) GR3030166T3 (de)
HK (1) HK1010988A1 (de)
IT (1) IT1272179B (de)
RU (1) RU2149185C1 (de)
WO (1) WO1995022985A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
EP0907659A1 (de) * 1996-05-10 1999-04-14 Schering Corporation Hepatitis c virus ns3 protease synthetische inhibitoren
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
EP1364961B1 (de) * 1996-09-12 2006-11-22 Vertex Pharmaceuticals Incorporated Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
US5861297A (en) * 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
US6436666B1 (en) 1996-10-17 2002-08-20 Chiron Corporation Protease regulator screening assay
WO1998037180A2 (en) * 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
US6280940B1 (en) 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2000040707A1 (en) * 1999-01-08 2000-07-13 Bristol-Myers Squibb Co. Modified forms of hepatitis c virus ns3 protease
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
JP2003514562A (ja) * 1999-11-23 2003-04-22 バイロファーマ・インコーポレイテッド ポリメラーゼ組成物およびその使用方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03000626A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
CN102372764A (zh) 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
CA2434845C (en) 2001-01-23 2013-11-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus replicons and replicon enhanced cells
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
ATE467680T1 (de) 2001-10-11 2010-05-15 Merck Sharp & Dohme Hepatitis-c-virus-impfstoff
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
CA2481171A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
EP1604020B1 (de) * 2003-02-13 2009-12-16 Merck & Co., Inc. Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
WO2006121468A1 (en) * 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
BRPI0607769A2 (pt) * 2005-02-28 2009-10-06 Genelabs Tech Inc pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais
US7834145B2 (en) * 2005-03-22 2010-11-16 Merck Sharp & Dohme Corp. HCV protease substrates
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
WO2006138744A2 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
JP2009513113A (ja) * 2005-10-28 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスｎｓ２／３活性のアッセイ法
WO2007145894A2 (en) 2006-06-08 2007-12-21 Merck & Co., Inc. A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제
US20100216161A1 (en) 2009-02-26 2010-08-26 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
EP2481807A3 (de) 2007-03-09 2013-04-03 Merck Sharp & Dohme Corp. In-vivo-HCV-Resistenz gegen antivirale Hemmer
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2012010663A1 (en) 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
WO2019147478A2 (en) 2018-01-18 2019-08-01 California Institute Of Technology Programmable protein circuits in living cells
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
WO2020047320A1 (en) 2018-08-31 2020-03-05 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
US11667676B2 (en) 2019-01-10 2023-06-06 California Institute Of Technology Synthetic system for tunable thresholding of protein signals

Also Published As

Publication number Publication date
GR3030166T3 (en) 1999-08-31
BR9506931A (pt) 1997-09-09
HK1010988A1 (en) 1999-07-02
ES2132644T3 (es) 1999-08-16
RU2149185C1 (ru) 2000-05-20
DK0746333T3 (da) 1999-11-01
DE69509504D1 (de) 1999-06-10
ITRM940092A1 (it) 1995-08-23
CA2182521C (en) 1999-07-06
DE69509504T2 (de) 1999-09-02
US5739002A (en) 1998-04-14
CA2182521A1 (en) 1995-08-31
AU691259B2 (en) 1998-05-14
EP0746333B1 (de) 1999-05-06
AU1822395A (en) 1995-09-11
ITRM940092A0 (it) 1994-02-23
JP3280384B2 (ja) 2002-05-13
IT1272179B (it) 1997-06-16
JPH10500005A (ja) 1998-01-06
WO1995022985A1 (en) 1995-08-31
EP0746333A1 (de) 1996-12-11

Similar Documents

Publication Publication Date Title
ATE179611T1 (de) Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv)
RU96119350A (ru) Способ репродукции in vitro протеолитической активности ns3 протеазы вируса гепатита c(нсу)
DE60018909D1 (de) Neue carbonyl-reduktase, gen davon und verfahren der anwendung derselben
CU22939A3 (es) Proceso para la síntesis de 1,3 dioles
ATE216400T1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
ATE317912T1 (de) Verfahren zur herstellung von beta-lactamen
PT846164E (pt) Metodologia para produzir, purificar e analisar polipeptidos com a actividade proteolitica da protease hcv ns3
MX9708679A (es) Sustratos disociables, solubles de la proteasa del virus de la hepatitis c.
MY131053A (en) 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
NO933503D0 (no) Dicytostelium dipeptidylaminopeptidase
ATE288445T1 (de) Herstellung von n-(n-(3,3-dimethylbutyl)-l-alpha- aspartyl)-l-phenylalanin-1-methylester durch verwendung vom l-alpha-aspartyl-l-phenylalanin-1- methylester als vorläufer
DE69613305D1 (de) Verbesserte enzymatische Kupplungsreaktion von N-geschützte L-Asparaginsäure und Phenylalaninmethylester
JPS6437298A (en) Production of c-terminal amidated peptide
GB0006537D0 (en) Assays and screening methods
AU5069800A (en) Novel gbv sequence
ATE236990T1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminonitrilen
EP1604020A4 (de) Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
DE59702822D1 (de) Verfahren zur herstellung von 2-fluor-1-cyclopropancarbonsäurederivaten durch reduktive enthalogenierung
EP0381331A3 (de) Gensequenzen, die modifizierte Reste in der Proteasedomäne des t-PAs codieren
EP0945512A3 (de) Serinproteasen
EP0316907A3 (en) Enzyme inhibitor and method of producing the same
Dang Thrombin and the Na (+)-induced allostery in serine proteases
RU97121351A (ru) Способ репродуцирования in vitro рнк-зависимых рнк полимеразной и терминальной нуклеотидилтрансферазной активностей, кодируемых вирусом гепатита с (hcv)
NO944411L (no) Endoprotease med en ny spaltningsspesifisitet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification